Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InnerDyne

This article was originally published in The Gray Sheet

Executive Summary

Biocompatible coating technology transfer to Boston Scientific will continue for use with stents, grafts, vena cava filters and other implantable medical devices. The decision builds on a 1996 agreement between the firms, which included an equity investment by Boston Scientific. InnerDyne has made public three similar contracts related to the technology in the device area. Third-party deals related to the coating and thermal ablation technology contribute to a 39% increase in revenues in the second quarter ended June 30 to $4.4 mil., InnerDyne reports, as the firm almost breaks even
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT010468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel